BioMarin Pharmaceutical Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BMRN research report →
Range $59 – $122
Price Chart
About the company
BioMarin Pharmaceutical Inc. specializes in creating and bringing to market treatments for individuals suffering from severe and often fatal rare disorders and other critical medical conditions. The company currently markets several key pharmaceutical products.
- CEO
- Alexander Hardy
- IPO
- 1999
- Employees
- 3,221
- HQ
- San Rafael, CA, US
Get TickerSpark's AI analysis on BMRN
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $11.70B
- P/E
- -650.11
- Fwd P/E
- 19.95
- PEG
- 6.29
- P/S
- 3.10
- P/B
- 1.81
- EV/EBITDA
- 33.21
- Div Yield
- 0.00%
- Gross Margin
- 75.42%
- Op Margin
- 6.51%
- Net Margin
- -0.52%
- ROE
- -0.31%
- ROIC
- -0.98%
Latest fiscal year · YoY change
- Revenue
- $3.22B+12.9%
- Gross Profit
- $2.48B+9.3%
- Op Income
- $533.48M
- Net Income
- $348.90M-18.3%
- EPS
- $1.82-19.1%
- OCF Growth
- +44.5%
- FCF Growth
- +52.5%
- 52W High
- $70.98
- 52W Low
- $49.26
- 50D MA
- $58.42
- 200D MA
- $58.51
- Beta
- 0.21
- RSI (14)
- 59
- Avg Volume
- 2.28M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
BioMarin posted its first-ever quarter above $1 billion in revenue, led by strong metabolic and VOXZOGO demand, while updating full-year guidance lower due to order timing and Middle East disruption.· November 2, 2026
- Q3 revenue topped $1 billion for the first time, with total revenue up 32% year over year.
- Metabolic conditions revenue was $744 million, up 44% year over year, driven by Galafold and Pombility/Opfolda.
- VOXZOGO revenue rose 12% year over year to $245 million, while children treated globally increased about 17%.
- Management added BMN-450 to the pipeline and continued to emphasize BMN-440 and BMN-333 as major longer-term development opportunities.
- Full-year 2026 guidance was cut, but management said the change reflects timing, not weaker underlying patient demand.
BioMarin reported third-quarter revenue above $1 billion for the first time, with revenue up 32% year over year. Metabolic conditions revenue was $744 million, up 44% year over year; Galafold revenue was $152 million, up from $138 million reported by Amicus in Q3 2025; Pombility and Opfolda revenue was $49 million, up from $31 million; and VOXZOGO revenue was $245 million, up 12% year over year. Non-GAAP diluted EPS was $0.23, affected by approximately $290 million of pretax Inozyme acquisition expenses, and Q3 included a $0.24 tax benefit that management said will normalize in Q4 and net to zero for the full year. For 2026, the company updated full-year revenue guidance to $3.8 billion to $3.9 billion and non-GAAP diluted EPS guidance to $2.80 to $3.10. Management said the revenue update was driven by deferral of about $70 million of expected orders and by Middle East-related disruption, not by patient demand, and said it still expects the business to grow in 2027; Pombility/Opfolda revenue growth should build into 2027 and beyond, and VOXZOGO should continue to grow in 2027.
Alexander Hardy framed the quarter as a proof point for BioMarin’s more diversified rare disease portfolio, highlighting strong commercial execution and the first quarter above $1 billion in revenue. He emphasized the strategic expansion of the pipeline with four new assets in 2026, including BMN-450, and said the company is building a broader, more resilient business across metabolic and skeletal conditions. His tone was upbeat and confident, especially around VOXZOGO’s future hypochondroplasia launch and the company’s ability to keep creating value through both internal development and business development.
Brian Mueller said Q3 non-GAAP diluted EPS was $0.23 and explained that Inozyme closed on August 31 and drove about $290 million of pretax expenses, or about $1.48 per share pretax, mostly related to acquired IPR&D. He also said the quarter included a $0.24 earnings-per-share tax benefit that will reverse in Q4 and net to zero for the full year, and reiterated that the acquisition should reduce full-year non-GAAP EPS by about $1.55. He noted non-GAAP SG&A rose 12% year over year due mainly to the Amicus integration, while revenue grew 32%. On guidance, he lowered 2026 revenue to $3.8 billion to $3.9 billion because of order timing and Middle East headwinds, but said the midpoint of EPS guidance would be effectively unchanged from August excluding the two new BD deals and the revenue change. He also said Amicus cost synergies are ahead of schedule and the company still expects about $220 million of non-GAAP cost synergies fully realized in 2028.
Analysts focused on three main issues: whether Amicus synergies are ahead of schedule, how much of Pombility/Opfolda growth is driven by competitor supply constraints, and how to think about VOXZOGO and BMN-333/440 development. Management said synergies are tracking ahead of plan and that the deal is now expected to be accretive within 9 months, potentially even in calendar 2026. On Pombility/Opfolda, Cristin Hubbard said much of the growth is still grounded in the medicine’s clinical profile and real-world evidence, but acknowledged a meaningful share of new starts in some European markets came from supply shortages at competitors and that revenue benefit from those starts should build into 2027 and beyond. On VOXZOGO, management said they expect continued 2027 growth and attributed it to international expansion, continued penetration, and the upcoming hypochondroplasia launch. On BMN-333 and BMN-440, Gregory Friberg said the BMN-333 phase 2/3 program is designed to test whether higher exposure can support a superiority case versus VOXZOGO, while BMN-440’s 2027 readout should provide PK, pharmacodynamic, and proof-of-mechanism data.
The call showed broad commercial momentum, with BioMarin crossing $1 billion in quarterly revenue and posting double-digit growth across key products. Management also pointed to several future growth drivers: hypochondroplasia for VOXZOGO, continued international expansion, BMN-450 in Fabry, and BMN-440/BMN-333 as new pipeline options. They were notably positive on integration execution, saying Amicus synergies are ahead of schedule and that the business is building momentum into 2027.
The main near-term risk is revenue timing, not demand, but it still forced a 2026 guidance cut after a roughly $70 million order deferral and added uncertainty from Middle East customer disruption. Management also said some of Pombility/Opfolda’s recent strength came from competitor supply constraints, which may not be durable. On the pipeline side, BMN-333 still has to prove its growth-velocity hypothesis, and BMN-440 will not have human proof-of-mechanism data until 2027.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 99.5%
- Shares Outstanding
- 193.69M
- Float Shares
- 192.75M
of shares held by institutions
588 13F filers
Buy/sell ratio 0.50. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for BMRN, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Daniel GoldmanHouse · NY10 | Sell | Mar 6, 23 | Filing → |
| Ro KhannaHouse · CA17 | Sell | Mar 14, 23 | Filing → |
| Ro KhannaHouse · CA17 | Buy | Dec 6, 22 | Filing → |
| Ro KhannaHouse · CA17 | Sell | May 10, 22 | Filing → |
| Josh GottheimerHouse · NJ05 | Sell | Oct 18, 21 | Filing → |
| Gilbert CisnerosHouse · CA31 | Buy | Dec 30, 20 | Filing → |
| Josh GottheimerHouse · NJ05 | Buy | Oct 16, 20 | Filing → |
| Josh GottheimerHouse · NJ05 | Sell | Sep 15, 20 | Filing → |
| Josh GottheimerHouse · NJ05 | Buy | Dec 11, 19 | Filing → |
| Josh GottheimerHouse · NJ05 | Buy | Dec 16, 19 | Filing → |
| Alan LowenthalHouse · CA47 | Sell | Aug 15, 19 | Filing → |
| Alan LowenthalHouse · CA47 | Sell | Aug 14, 19 | Filing → |
| Alan LowenthalHouse · CA47 | Sell | Aug 14, 19 | Filing → |
| Alan LowenthalHouse · CA47 | Sell | Aug 15, 19 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock, Inc. | 20.74M | ▲ 290.34K |
| Vanguard Group Inc | 18.13M | ▼ 454.74K |
| Primecap Management Co | 14.99M | ▲ 798.81K |
| Dodge & Cox | 14.63M | ▼ 219.19K |
| Vanguard Capital Management LLC | 8.72M | ▼ 19.89K |
| Vanguard Portfolio Management LLC | 8.37M | ▼ 276.79K |
| State Street Corp | 8.34M | ▲ 538.82K |
| Norges Bank | 8.21M | ▲ 8.21M |
| Fmr LLC | 7.34M | ▲ 2.52M |
| Viking Global Investors LP | 7.17M | ▼ 443.39K |
| Deep Track Capital, LP | 6.37M | ▲ 3.07M |
| Vestal Point Capital, LP | 5.53M | ▼ 500.00K |
Held by 658 ETFs
Biggest fund positions in BMRN by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 18, 26 | Friberg Gregory R | sell | 5,147 |
| Sep 30, 26 | Friberg Gregory R | other | 4,086 |
| Sep 10, 26 | Plenge Robert M | other | 6,140 |
| Sep 10, 26 | Plenge Robert M | other | 0 |
| Sep 2, 26 | Davis George Eric | sell | 17,557 |
| Jun 2, 26 | Countouriotis Athena | other | 7,490 |
| Jun 2, 26 | Walbert Timothy P | other | 7,490 |
| Jun 2, 26 | Ho Maykin | other | 7,490 |
| Jun 2, 26 | HOMBACH ROBERT J. | other | 7,490 |
| Jun 2, 26 | Enyedy Mark J | other | 7,490 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our BMRN coverage
Recent articles, reports, and earnings notes.
Want a deeper read on BMRN?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
BioMarin Pharmaceutical Bets on Amicus Growth as VOXZOGO Competition Concerns Mount
marketbeat.com · Nov 19
BioMarin Pharmaceutical Inc. (BMRN) Presents at Jefferies Global Healthcare Conference 2026 Transcript
seekingalpha.com · Nov 17
BioMarin Pharmaceutical Sees $2.6 Billion Sales Potential in Amicus Drugs as VOXZOGO Expansion Looms
marketbeat.com · Nov 16
BioMarin Pharmaceutical Inc. (BMRN) Presents at UBS Global Biopharma Conference 2026 Transcript
seekingalpha.com · Nov 16
BioMarin Pharmaceutical Hits $1 Billion Revenue Milestone, Advances Rare-Disease Pipeline
marketbeat.com · Nov 11
BioMarin Pharmaceutical Inc. (BMRN) Presents at Stifel 2026 Healthcare Conference 2026 Transcript
seekingalpha.com · Nov 11
Bfsg LLC Buys 17,538 Shares of BioMarin Pharmaceutical Inc. $BMRN
defenseworld.net · Nov 6
Traders Buy Large Volume of BioMarin Pharmaceutical Call Options (NASDAQ:BMRN)
defenseworld.net · Nov 5
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
